Product Description
DNA Damage Response (DDR) is a cellular surveillance to maintain the integrity of DNA and genome stability. DDR comprises of cell-cycle checkpoint pathways and DNA damage repair mechanisms which are important steps of the cell cycle and cell survival. When DNA damage cannot be repaired, the DDR activates the mechanisms to stop cell division and replication, or to initiate programmed cell death. Dysfunction of the DDR mechanisms a key feature of cancer and inhibition to DDR has been shown to be an effective cancer treatment. One of the best-known DDR inhibitors is PARP inhibitor which can effectively kill cancers with homologous recombination deficient (HRD) such as those carrying BRCA mutations. After the four FDA-approved PARP inhibitors have been successfully treated cancer patients in the market for several years, the patients have become resistance to the PARP inhibitors, poses a significant issue to the continuous use of PARP inhibitors and desperate need of alternative treatment options. (Sourced from: http://www.avelostx.com/en/sub/research/pipeline.asp)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Avelos
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|